How have HELX shares performed in 2024?

Franklin Genomic Advancements ETF's stock was trading at $30.47 on January 1st, 2024. Since then, HELX stock has increased by 1.6% and is now trading at $30.9451. View the best growth stocks for 2024 here .

What does HELX invest in?

Franklin Genomic Advancements ETF is a equity fund issued by Franklin Templeton Investments. HELX focuses on theme investments. The fund's investments total to approximately $9.29 million assets under management.

What stocks does Franklin Genomic Advancements ETF hold?

HELX invests in 65 holdings. Some of the stocks in their portfolio include Medpace (MEDP) , Vertex Pharmaceuticals (VRTX) , Thermo Fisher Scientific (TMO) , Regeneron Pharmaceuticals (REGN) , Eli Lilly and Company (LLY) , Krystal Biotech (KRYS) , Danaher (DHR) , Bruker (BRKR) , Natera (NTRA) and AstraZeneca (AZN) .

What is the management fee for Franklin Genomic Advancements ETF?

Franklin Genomic Advancements ETF's management fee is 0.50% and has no other recorded expenses or fee waivers. The net expense ratio for HELX is 0.50%.

How do I buy shares of Franklin Genomic Advancements ETF?

Shares of HELX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

BATS:HELX

Franklin Genomic Advancements ETF (HELX) Price, Holdings, & News

→ Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad)

Free HELX Stock Alerts

$30.95

+0.31 (+1.01%)

(As of 05/3/2024 ET)

Compare

Today's Range: $30.91
▼
$30.96
50-Day Range: $29.32
▼
$32.92
52-Week Range: N/A

Volume: 896 shs
Average Volume: N/A
Market Capitalization: $9.28 million

Assets Under Management: $9.29 million
Dividend Yield: N/A
Net Expense Ratio: 0.50%

Stock Analysis Chart Holdings Ratings

Get Franklin Genomic Advancements ETF alerts:

About Franklin Genomic Advancements ETF

The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that is based on the Solactive Genomics index. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is managed by Franklin Templeton.

HELX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HELX ETF News Headlines

April 23, 2024 | lse.co.uk

Franklin Catholic Princ Em Sov Ucits Etf Share Price (CATHEM.MI)

March 27, 2024 | money.usnews.com

Franklin U.S. Treasury Bond ETF

May 6, 2024 | Altimetry (Ad)

Urgent Nvidia Warning

Could Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.

November 25, 2023 | lse.co.uk

Franklin Msci China Paris Alig Ucits Etf Share Price (FRCP.MI)

November 17, 2023 | lse.co.uk

Franklin Emerging Markets Ucits Etf Share Price (FLXE.MI)

February 25, 2023 | morningstar.com

BMO ARK Genomic Revolution ETF Series

See More Headlines

Receive HELX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Franklin Genomic Advancements ETF and its competitors with MarketBeat's FREE daily newsletter.

Fund Details

Issuer: Franklin Templeton Investments
Fund Name: Franklin Genomic Advancements ETF
Tax Classification: Regulated Investment Company
Stock Exchange: BATS
Current Symbol: BATS:HELX
Inception Date: 2/25/2020
Fund Manager: Matthew J.Moberg, Joyce Lin
Web: N/A
Phone: N/A

Fund Focus

Asset Class: Equity
Benchmark: N/A
Category: Strategy
Focus: Theme
Development Level: Blended Development
Region: Global
Number of Holdings: 65

Fund Statistics

Assets Under Management: $9.29 million
Average Daily Volume: $0.00
Discount/Premium: -0.01%

Administrator, Advisor and Custodian

Administrator: Franklin Templeton Services, LLC
Advisor: Franklin Advisers, Inc.
Custodian: State Street Bank and Trust Company
Distributor: Franklin Templeton Distributors, Inc.
Transfer Agent: State Street Bank and Trust Company
Trustee: N/A
Lead Market Maker: Citadel

Miscellaneous

Outstanding Shares: 300,000
Beta: 0.96
Creation Unit: 50,000
Creation Fee: $200.00

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Ad InvestorPlace

Elon’s New Device is About to Shock the World

Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.”

Click here to see the details because there’s a lot of money at stake.

Franklin Genomic Advancements ETF Expenses

Type	HELX	Theme ETFs	Equity ETFs	BATS ETFs	All ETFs
Management Fee	0.50%	0.57%	0.54%	0.56%	0.51%
Other Expenses	0.00%	0.72%	0.54%	0.51%	0.58%
Total Expense	0.50%	0.72%	0.70%	0.68%	0.70%
Fee Waiver	0.00%	-0.76%	-0.55%	-0.34%	-0.57%
Net Expense	0.50%	0.59%	0.60%	0.63%	0.58%

Franklin Genomic Advancements ETF (HELX) Holdings & Exposure

Top 10 HELX Holdings

HELX Sector Exposure

HELX Industry Exposure

Full Holdings Details

Similar ETFs

HELX ETF - Frequently Asked Questions

How have HELX shares performed in 2024?: Franklin Genomic Advancements ETF's stock was trading at $30.47 on January 1st, 2024. Since then, HELX stock has increased by 1.6% and is now trading at $30.9451.
View the best growth stocks for 2024 here.
What does HELX invest in?: Franklin Genomic Advancements ETF is a equity fund issued by Franklin Templeton Investments. HELX focuses on theme investments. The fund's investments total to approximately $9.29 million assets under management.
What stocks does Franklin Genomic Advancements ETF hold?: HELX invests in 65 holdings. Some of the stocks in their portfolio include Medpace (MEDP), Vertex Pharmaceuticals (VRTX), Thermo Fisher Scientific (TMO), Regeneron Pharmaceuticals (REGN), Eli Lilly and Company (LLY), Krystal Biotech (KRYS), Danaher (DHR), Bruker (BRKR), Natera (NTRA) and AstraZeneca (AZN).

What is the management fee for Franklin Genomic Advancements ETF?: Franklin Genomic Advancements ETF's management fee is 0.50% and has no other recorded expenses or fee waivers. The net expense ratio for HELX is 0.50%.
How do I buy shares of Franklin Genomic Advancements ETF?: Shares of HELX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (BATS:HELX) was last updated on 5/6/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial